CHAMPIONS ONCOLOGY, INC.
Business
Champions Oncology is a technology-enabled research organization providing computational and experimental research platforms for drug discovery and development. The company operates three primary business lines: research services utilizing its proprietary Patient Derived Xenograft (PDX) models and associated Datacenter; a Software as a Service offering (Lumin Bioinformatics) providing oncology research tools via subscription; and an early-stage drug discovery and development business focused on targeted therapy, immuno-oncology, and cell therapy. The company serves pharmaceutical and biotechnology customers across North America, Europe, and Asia.
Summary from 10-K filed 2025-07-23
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Oncology revenue | 57 | 50 | 54 | 49 | 41 | |
| Cost of oncology revenue | 28 | 29 | 30 | 24 | 21 | |
| Research and development | 7 | 10 | 12 | 9 | 7 | |
| Sales and marketing | 8 | 7 | 7 | 6 | 6 | |
| General and administrative | 9 | 11 | 10 | 9 | 7 | |
| Loss on disposal of equipment | 293,000 | 435,000 | 0 | — | — | |
| Total costs and operating expenses | 52 | 58 | 59 | 49 | 41 | |
| Income (loss) from operations | 5 | −7 | −5 | 607,000 | 366,000 | |
| Other income, net | 73,000 | 48,000 | −11,000 | −24,000 | 71,000 | |
| Income (loss) before income tax expense | 5 | −7 | −5 | 583,000 | 437,000 | |
| Benefit for income tax | −75,000 | −32,000 | 68,000 | 35,000 | 75,000 | |
| Net income (loss) | 5 | −7 | −5 | 548,000 | 362,000 | |
| basic (in dollars per share) | 0.34 | −0.54 | −0.39 | 0.04 | 0.03 | |
| diluted (in dollars per share) | 0.33 | −0.54 | −0.39 | 0.04 | 0.02 | |
| basic (in shares) | 14 | 14 | 14 | 13 | 13 | |
| diluted (in shares) | 14 | 14 | 14 | 14 | 15 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Cash | 10 | 3 | 10 | 9 | 5 | |
| Accounts receivable, net | 11 | 10 | 8 | 10 | 7 | |
| Prepaid expenses and other current assets | 1 | 1 | 1 | 1 | 957,000 | |
| Total current assets | 22 | 14 | 19 | 20 | 13 | |
| Operating lease right-of-use assets, net | 5 | 6 | 7 | 8 | 9 | |
| Property and equipment, net | 4 | 6 | 7 | 7 | 6 | |
| Other long term assets | 185,000 | 185,000 | 15,000 | 15,000 | 15,000 | |
| Goodwill | 335,000 | 335,000 | 335,000 | 335,000 | 335,000 | |
| Total assets | 32 | 26 | 34 | 35 | 28 | |
| Accounts payable | 4 | 6 | 5 | 3 | 2 | |
| Accrued liabilities | 3 | 2 | 2 | 2 | 2 | |
| Current portion of operating lease liabilities | 1 | 1 | 1 | 1 | 818,000 | |
| Other current liabilities | 135,000 | 150,000 | 145,000 | — | — | |
| Deferred revenue | 15 | 12 | 13 | 11 | 6 | |
| Total current liabilities | 24 | 22 | 22 | 17 | 11 | |
| Non-current portion operating lease liabilities | 5 | 6 | 7 | 8 | 9 | |
| Other non-current liabilities | 85,000 | 401,000 | 551,000 | 391,000 | 181,000 | |
| Total liabilities | 29 | 28 | 30 | 26 | 20 | |
| Common stock, $.001 par value; 200,000,000 shares authorized; 13,897,503 and 13,714,099 shares issued; and 13,777,170 and 13,593,766 shares outstanding at April 30, 2025 and 2024, respectively | 14,000 | 14,000 | 14,000 | 14,000 | 13,000 | |
| Treasury Stock, at cost | −708,000 | −708,000 | −74,000 | 0 | — | |
| Additional paid-in capital | 84 | 83 | 82 | 81 | 80 | |
| Accumulated deficit | −80 | −85 | −77 | −72 | −73 | |
| Total stockholders' equity (deficiency) | 4 | −2 | 5 | 9 | 7 | |
| Total liabilities and stockholders' equity (deficiency) | 32 | 26 | 34 | 35 | 28 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 654,000 | 1 | 864,000 | 912,000 | 598,000 | |
| Depreciation and amortization expense | 2 | 2 | 2 | 2 | 1 | |
| Decrease in uncertain tax position | −181,000 | 0 | — | — | — | |
| Operating lease right-of-use assets | 1 | 1 | 952,000 | 786,000 | 398,000 | |
| Allowance and estimated credit losses | −272,000 | 476,000 | 195,000 | 292,000 | 49,000 | |
| Accounts receivable | −1 | −2 | 1 | −3 | −2 | |
| Prepaid expenses and other current assets | 144,000 | −167,000 | −184,000 | −187,000 | −572,000 | |
| Other long term assets | 0 | −169,000 | 0 | — | — | |
| Accounts payable | −2 | 465,000 | 2 | 974,000 | −1 | |
| Accrued liabilities | 395,000 | −109,000 | −145,000 | 183,000 | −316,000 | |
| Operating lease liabilities | −1 | −1 | −907,000 | −631,000 | −242,000 | |
| Deferred revenue | 3 | −683,000 | 2 | — | — | |
| Net cash provided by (used in) operating activities | 7 | −6 | 4 | 6 | −2 | |
| Purchase of property and equipment | −389,000 | −836,000 | −3 | −2 | −3 | |
| Net cash used in investing activities | −389,000 | −836,000 | −3 | −2 | −3 | |
| Proceeds from exercise of options | 320,000 | 253,000 | 85,000 | 207,000 | — | |
| Repurchases of common stock | 0 | −634,000 | −74,000 | 0 | — | |
| Finance lease payments | −150,000 | −146,000 | 0 | 0 | −174,000 | |
| Net cash provided by (used in) financing activities | 170,000 | −527,000 | 11,000 | 207,000 | 1 | |
| Increase (decrease) in cash | 7 | −8 | 1 | 4 | −4 | |
| Equipment purchased in accounts payable | 197,000 | 0 | — | — | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CHAMPIONS ONCOLOGY, INC.'s CIK number?
CHAMPIONS ONCOLOGY, INC.'s SEC CIK number is 0000771856 (771856). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CHAMPIONS ONCOLOGY, INC.'s SEC filings?
All of CHAMPIONS ONCOLOGY, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CHAMPIONS ONCOLOGY, INC. last report earnings?
CHAMPIONS ONCOLOGY, INC. (CSBR) most recently filed an earnings 8-K with the SEC on Mar 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-017259). This is CHAMPIONS ONCOLOGY, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is CHAMPIONS ONCOLOGY, INC.'s most recent earnings 8-K?
CHAMPIONS ONCOLOGY, INC.'s latest earnings 8-K (Item 2.02) was filed Mar 12, 2026 under accession 0001628280-26-017259. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CHAMPIONS ONCOLOGY, INC.'s latest earnings 8-K →
Look up any company's CIK number →